(Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta, Canada

Abstract

Purpose

We provide a description of the diagnostic odyssey for a cohort of children seeking diagnosis of a rare genetic disorder in terms of the time from initial consultation to most recent visit or receipt of diagnosis, the number of tests per patient, and the types of tests received.

Methods

Retrospective chart review of 299 children seen at the Alberta Children’s Hospital (ACH) Genetics Clinic (GC) for whom the result of at least one single-gene test, gene panel, or chromosome microarray analysis (CMA) was recorded.

Results

Of 299 patients, 90 (30%) received a diagnosis in the period of the review. Patients had an average of 5.4 tests each; 236 (79%) patients received CMA; 172 (58%) patients received single-gene tests and 34 (11%) received gene panels; 167 (56%) underwent imaging/electrical activity studies. The mean observation period was 898 days (95% confidence interval [CI] 791, 1004). Among patients with visits recorded prior to visiting ACH GC, 43% of the total observation time occurred prior to the GC.

Conclusion

As genomic technologies expand, the nature of the diagnostic odyssey will change. This study has outlined the current standard of care in the ACH GC, providing a baseline against which future changes can be assessed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Wakap SN. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–173.

    Article  Google Scholar 

  2. 2.

    Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179:885–892.

    Article  Google Scholar 

  3. 3.

    Chae JH, et al. Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders. J Med Genet. 2015;52:208–216.

    CAS  Article  Google Scholar 

  4. 4.

    Kingsmore SF, et al. Adopting orphans: comprehensive genetic testing of Mendelian diseases of childhood by next-generation sequencing. Expert Rev Mol Diagn. 2011;11:855–868.

    CAS  Article  Google Scholar 

  5. 5.

    Shashi V, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med. 2013;16:176–182.

    Article  Google Scholar 

  6. 6.

    Tsiplova K, et al. A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med. 2017;19:1268.

    Article  Google Scholar 

  7. 7.

    Boycott K, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: position statement of the Canadian College of Medical Geneticists. J Med Genet. 2015;52:431–437.

    CAS  Article  Google Scholar 

  8. 8.

    Dragojlovic N, et al. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. Genet Med. 2020;22:292–200.

    Article  Google Scholar 

  9. 9.

    Soden SE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168.

    Article  Google Scholar 

  10. 10.

    Stark Z, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867.

    PubMed  Google Scholar 

  11. 11.

    Tan TY, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171:855–862.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    van Nimwegen KJM, et al. The diagnostic pathway in complex paediatric neurology: a cost analysis. Eur J Paediatr Neurol. 2015;19:233–239.

    Article  Google Scholar 

  13. 13.

    Monroe GR, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med. 2016;18:949–956.

    CAS  Article  Google Scholar 

  14. 14.

    Thevenon J, et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic test. Clin Genet. 2016;89:700–707.

    CAS  Article  Google Scholar 

  15. 15.

    Palmer EE, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: evidence of clinical utility and cost effectiveness. Mol Genet Genom Med. 2018;6:186–199.

    CAS  Article  Google Scholar 

  16. 16.

    Schofield D, et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. NPJ Genom Med. 2017;2:1–7.

    Article  Google Scholar 

  17. 17.

    Oei K, et al. Genetic testing among children in a complex care program. Children. 2017;4:42.

    Article  Google Scholar 

  18. 18.

    Alberta Children’s Hospital Foundation. Alberta Children’s Hospital Foundation: our hospital. 2020. http://www.childrenshospital.ab.ca/site/PageNavigator/hospital/our_hospital.

  19. 19.

    StataCorp. Stata statistical software: release 12. 2011, StataCorp LP: College Station, TX.

  20. 20.

    Dragojlovic N, et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study. Genet Med. 2018;20:1013.

    PubMed  Google Scholar 

  21. 21.

    Stavropoulos DJ, et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPJ Genom Med. 2016;1:15012.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was funded by a Seed Grant from the Cumming School of Medicine (CSM) and Alberta Health Services (AHS) Clinical Research Fund at the University of Calgary. C.M-I. is funded by an Alberta Innovates Postgraduate Scholarship and a Network of Alberta Health Economists (NOAHE) Fellowship award. D.A.M. is funded by the Arthur J.E. Child Chair in Rheumatology Outcomes Research and a Canada Research Chair in Health Services and Systems Research.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christine Michaels-Igbokwe PhD.

Ethics declarations

Disclosure

The authors declare no conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Michaels-Igbokwe, C., McInnes, B., MacDonald, K.V. et al. (Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta, Canada. Genet Med (2020). https://doi.org/10.1038/s41436-020-00975-0

Download citation

Keywords

  • genetic disorders
  • pediatric
  • children
  • diagnostic odyssey

Search